MoU signed to facilitate regulatory process for biosimilars

An MoU has been signed between CSIR-CCMB and the IPC to facilitate the regulatory process for biosimilars and herbal drugs.

By: IANS | | Published: April 29, 2019 10:29 am

Documentation and characterisation of Indian herbal drugs and phytopharmaceuticals will lead to a significant usage and their export. © Shutterstock

Council of Scientific and Industrial Research’s constituent laboratory, the Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, and the Indian Pharmacopeia Commission (IPC), Ghaziabad, have joined hands to facilitate the regulatory process for biosimilars and herbal drugs, as per a statement here on Sunday. Also Read - Moody's questions India's Aadhaar

Also Read - G20 Summit 2023: Will Xi Jinping attend the summit?

The scope of the memorandum of understanding (MoU) signed between CSIR-CCMB and the IPC is the development of biopharmaceutical reference standards and impurities therein, development of monographs for important Monoclonal Antibodies and identification of herbal drugs based on DNA Barcode analysis, a CCMB statement said. Also Read - Proper nutrition policy can alleviate deaths associated with diet in India

Use of biologics – biological products that function as drugs against diseases – also known as biosimilars, are expanding their presence rapidly in the healthcare sector, including in India.

A 2017 report by the Confederation of Indian Industry (CII) predicts that the biosimilars market in India, that is currently worth about Rs 15,000 crore, is expected to cross the staggering Rs 2,50,000 crore-mark by 2030.

Emergence of biopharmaceutical drugs as a preferred choice for therapy over conventional pharma drugs, requires concerted efforts by various sectors within the country towards production, characterisation and validation of indigenously developed products, the CCMB said.

The agreement was signed by CSIR-CCMB Director Rakesh Mishra and IPC’s Secretary-cum-Scientific Director G.N. Singh.

This collaboration, which has come into force with immediate effect, is very important in the current scenario owing to the increase in use of therapeutic proteins and herbal drugs for various diseases, the statement said.

Documentation and characterisation of Indian herbal drugs and phytopharmaceuticals will lead to a significant usage and their export.

This collaborative project will be executed at par with pharmacopeia standards of other countries, it said.

Scientific validation and characterization of herbal drugs will not only help authentication of such drugs but also will bring credibility for this industry, the CCMB added.

Published : April 29, 2019 10:29 am

Two existing drugs can be effective against leukaemia: Study

High levels of PCBs in blood can cause early death: Study

About The health Site

TheHealthSite.com is India's largest health site with more than 40 lakh unique visitors per month. We focus on fitness, beauty, health, pregnancy and more.

Most popular health and wellness website in India in 2012 at the Website of the year awards.

health@corp.india.com

+91 – 22 – 6697 1234

91 – 22 – 2490 0302.

ZEE ENTERTAINMENT ENTERPRISES LTD, 18th floor, A-Wing, Marathon Futurex, N. M. Joshi Marg, Lower Parel, Mumbai, Maharashtra 400013.

We respect your privacy

Two existing drugs can be effective against leukaemia: Study

High levels of PCBs in blood can cause early death: Study

About The health Site

Useful Links